| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Solve Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $296.39M | Series A | 11/17/2025 | $296.39M | $426.7M | $4.41 | Abingworth, Ally Bridge Group, B Capital, Balyasny Asset Management, Merck & Co., SymBiosis, Alexandria Venture Investments, AyurMaya Capital Management, DC Global Ventures, Matrix Capital Management, Decheng Capital, General Atlantic, Surveyor Capital | ||||
 | Spectrum Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Spinogenix | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $24.4M | Series D | 11/21/2025 | $9.8M | $365.97M | $34.92 | Undisclosed Investors | ||||
 | Star Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Stratos Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Strive Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Syntis Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Tenvie | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $200M | Series A | 1/8/2025 | $158.05M | $391.74M | $1.00 | ARCH Venture Partners, F-Prime Capital, Mubadala Capital | ||||
 | Tetherex Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.65M | Series B | 4/18/2018 | $63.95M | $366.68M | $21.32 | MPM Capital, Philip Jones | ||||
 | TMRW Life Sciences | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $238.98M | Series E | 3/26/2026 | $25.11M | $75.5M | $0.04 | Undisclosed Investors | ||||
 | Treadwell Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | TRexBio | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $218.62M | Series B | 1/27/2026 | $134.06M | $268.67M | $3.09 | Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors, Delos Capital, Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson Innovation, Alexandria Venture Investments, Polaris Partners | ||||
 | TwinStrand Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Vascular Therapies | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Wellth | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Xalud Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $72.64M | Series C | 8/24/2021 | $32.75M | $259.4M | $2.80 | PBM Capital Group | ||||
 | Adaptive Innovations | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $60M | Series A | 6/2/2026 | $50M | $242.97M | $6.26 | Felicis, Optum Ventures, Sunflower Capital, Conviction, BoxGroup, SV Angel, Dorm Room Fund, Constellation, Bain Capital Ventures | ||||
 | Alleviant Medical | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $182.73M | Series 2 | 1/14/2025 | $91.4M | $258.67M | $1.28 | Gilde Healthcare, Omega Funds, S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Corporation | ||||
 | Ampersand Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $109.61M | Series B | 3/19/2025 | $65M | $360.94M | $5.80 | Flagship Pioneering, Eli Lilly & Company | ||||
 | Amylyx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $203.25M | Series C-1 | 7/20/2021 | $107.33M | $541.01M | $10.27 | Viking Global Investors, Bain Capital Life Sciences, Perceptive Advisors, Rock Springs Capital, Woodline Partners, Marshall Wace, Tybourne Capital Management, Verition Fund Management, aMoon Fund, Falcon Edge, Morningside Ventures, 683 Capital Management, Belinda Termeer, Polaris Founders Capital | ||||
 | Annexon Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Antiva Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | ArriVent Biopharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $260M | Series B | 12/16/2022 | $110M | $375.08M | $1.05 | Undisclosed Investors | ||||
 | ARS Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $76.55M | Series D | 8/31/2021 | $55M | $310.11M | $5.89 | SR One, RA Capital Management, Deerfield | ||||